Christopher A Eide

11PUBLICATIONS
95CO-AUTHORS
Predictive and prognostic markersHaematological tumoursGene and molecular therapyMolecular targetsMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Nov 24, 2025
A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies.

Stephen E Kurtz, Christopher A Eide, Andy Kaempf

|Jul 15, 2025
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

Serena Muratcioglu, Christopher A Eide, Chien-Lun Hung

|May 21, 2025
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.

Curtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena

|Feb 26, 2025
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia.

Basil Allen, Daniel Bottomly, Thomas Köhnke

|Mar 07, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia.

Rucha V Modak, Katia G de Oliveira Rebola, John McClatchy

|Sep 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.

Christopher A Eide, Stephen E Kurtz, Andy Kaempf

Pageof 2

Frequent Collaborators

8 joint publications

Brian J Druker

7 joint publications

Stephen E Kurtz

7 joint publications

Jeffrey W Tyner

6 joint publications

Nicola Long